Spectral AI to Showcase DeepView System at American Burn Association Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MDAI?
Source: Newsfilter
- Event Participation: Spectral AI will showcase its DeepView® System at the American Burn Association Annual Meeting from April 14-17, 2026, in Orlando, Florida, attracting over 2,200 clinicians and researchers, which will enhance the company's influence in the burn care industry.
- Product Demonstration: The DeepView System combines multispectral imaging with a proprietary AI algorithm to rapidly assess the healing potential of burn wounds, enabling clinicians to make faster treatment decisions, which is expected to significantly improve patient outcomes and reduce healthcare costs.
- FDA Application Progress: Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the FDA in June 2025, and if approved, it will further accelerate the product's market entry and strengthen the company's competitive position in medical diagnostics.
- Industry Recognition: Spectral AI has been named one of TIME's Top HealthTech Companies of 2025, highlighting its leadership in medical technology innovation and is expected to attract more investor interest in its future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDAI
Wall Street analysts forecast MDAI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.990
Low
3.00
Averages
4.50
High
6.00
Current: 1.990
Low
3.00
Averages
4.50
High
6.00
About MDAI
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Spectral AI to Showcase DeepView System at American Burn Association Annual Meeting
- Event Participation: Spectral AI will showcase its DeepView® System at the American Burn Association Annual Meeting from April 14-17, 2026, in Orlando, Florida, attracting over 2,200 clinicians and researchers, which will enhance the company's influence in the burn care industry.
- Product Demonstration: The DeepView System combines multispectral imaging with a proprietary AI algorithm to rapidly assess the healing potential of burn wounds, enabling clinicians to make faster treatment decisions, which is expected to significantly improve patient outcomes and reduce healthcare costs.
- FDA Application Progress: Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the FDA in June 2025, and if approved, it will further accelerate the product's market entry and strengthen the company's competitive position in medical diagnostics.
- Industry Recognition: Spectral AI has been named one of TIME's Top HealthTech Companies of 2025, highlighting its leadership in medical technology innovation and is expected to attract more investor interest in its future growth potential.
See More
Spectral AI Appoints New CFO David McGuire
- New CFO Appointment: Spectral AI announced the appointment of David McGuire as CFO effective May 4, 2026, indicating the company's strategic emphasis on financial management with McGuire's over 20 years of finance and accounting experience.
- Extensive Industry Background: McGuire most recently served as CAO at Solo Brands and held the positions of deputy CFO and chief accounting officer at EZCORP, where he oversaw financial operations and capital markets activities, suggesting his expertise will positively impact Spectral AI.
- Market Reaction: Despite the announcement of the new appointment, Spectral AI's shares fell by 1.20%, reflecting a cautious market sentiment regarding the company's future financial performance, which may affect investor confidence.
- Strategic Implications: McGuire's appointment not only enhances the company's financial management capabilities but may also support future capital market activities and strategic initiatives, helping the company maintain its competitive edge in a challenging market.
See More
Spectral AI Appoints New CFO to Drive Commercialization
- Executive Appointment: Spectral AI has announced the appointment of David McGuire as Chief Financial Officer, effective May 4, 2026, aiming to strengthen the company's financial leadership and strategic readiness for the commercialization of the DeepView® System.
- Extensive Experience: McGuire brings over 20 years of finance and accounting experience, having held executive roles at Solo Brands and EZCORP, where he oversaw financial reporting, internal controls, and capital markets activities, which is expected to positively impact Spectral AI's financial infrastructure.
- Strategic Goals: McGuire expressed his eagerness to collaborate with the team to advance the company's strategic priorities and enhance long-term shareholder value, indicating the company's confidence and commitment to future growth.
- Technological Innovation: Spectral AI's DeepView System aims to revolutionize wound care management by providing objective assessments of burn wound healing potential, expected to improve patient outcomes and reduce healthcare costs, further solidifying its position in the health tech sector.
See More
SPECTRAL AI INC NAMES DAVID MCGUIRE CFO, STARTING MAY 4, 2026
Overview of Spectral AI: Spectral AI is a company focused on developing advanced artificial intelligence solutions, particularly in the field of healthcare and diagnostics.
Leadership Appointment: David McGuire has been appointed as the Chief Financial Officer (CFO) of Spectral AI, bringing extensive experience in financial management and strategic planning.
Future Goals: The company aims to enhance its operational efficiency and expand its market presence under McGuire's financial leadership.
Impact on Healthcare: Spectral AI's innovations are expected to significantly improve diagnostic processes and patient outcomes in the healthcare sector.
See More
SPECTRAL AI APPOINTS DAVID MCGUIRE, CPA, AS CFO
- New Appointment: Spectral AI has named David McGuire as its Chief Financial Officer (CFO).
- Background: David McGuire is a Certified Public Accountant (CPA) with extensive experience in financial management.
See More
Spectral AI (MDAI) Q4 2025 Earnings Transcript
See More
Spectral AI to Showcase DeepView System at American Burn Association Annual Meeting
- Event Participation: Spectral AI will showcase its DeepView® System at the American Burn Association Annual Meeting from April 14-17, 2026, in Orlando, Florida, attracting over 2,200 clinicians and researchers, which will enhance the company's influence in the burn care industry.
- Product Demonstration: The DeepView System combines multispectral imaging with a proprietary AI algorithm to rapidly assess the healing potential of burn wounds, enabling clinicians to make faster treatment decisions, which is expected to significantly improve patient outcomes and reduce healthcare costs.
- FDA Application Progress: Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the FDA in June 2025, and if approved, it will further accelerate the product's market entry and strengthen the company's competitive position in medical diagnostics.
- Industry Recognition: Spectral AI has been named one of TIME's Top HealthTech Companies of 2025, highlighting its leadership in medical technology innovation and is expected to attract more investor interest in its future growth potential.
See More
Spectral AI Appoints New CFO David McGuire
- New CFO Appointment: Spectral AI announced the appointment of David McGuire as CFO effective May 4, 2026, indicating the company's strategic emphasis on financial management with McGuire's over 20 years of finance and accounting experience.
- Extensive Industry Background: McGuire most recently served as CAO at Solo Brands and held the positions of deputy CFO and chief accounting officer at EZCORP, where he oversaw financial operations and capital markets activities, suggesting his expertise will positively impact Spectral AI.
- Market Reaction: Despite the announcement of the new appointment, Spectral AI's shares fell by 1.20%, reflecting a cautious market sentiment regarding the company's future financial performance, which may affect investor confidence.
- Strategic Implications: McGuire's appointment not only enhances the company's financial management capabilities but may also support future capital market activities and strategic initiatives, helping the company maintain its competitive edge in a challenging market.
See More
Spectral AI Appoints New CFO to Drive Commercialization
- Executive Appointment: Spectral AI has announced the appointment of David McGuire as Chief Financial Officer, effective May 4, 2026, aiming to strengthen the company's financial leadership and strategic readiness for the commercialization of the DeepView® System.
- Extensive Experience: McGuire brings over 20 years of finance and accounting experience, having held executive roles at Solo Brands and EZCORP, where he oversaw financial reporting, internal controls, and capital markets activities, which is expected to positively impact Spectral AI's financial infrastructure.
- Strategic Goals: McGuire expressed his eagerness to collaborate with the team to advance the company's strategic priorities and enhance long-term shareholder value, indicating the company's confidence and commitment to future growth.
- Technological Innovation: Spectral AI's DeepView System aims to revolutionize wound care management by providing objective assessments of burn wound healing potential, expected to improve patient outcomes and reduce healthcare costs, further solidifying its position in the health tech sector.
See More
SPECTRAL AI INC NAMES DAVID MCGUIRE CFO, STARTING MAY 4, 2026
Overview of Spectral AI: Spectral AI is a company focused on developing advanced artificial intelligence solutions, particularly in the field of healthcare and diagnostics.
Leadership Appointment: David McGuire has been appointed as the Chief Financial Officer (CFO) of Spectral AI, bringing extensive experience in financial management and strategic planning.
Future Goals: The company aims to enhance its operational efficiency and expand its market presence under McGuire's financial leadership.
Impact on Healthcare: Spectral AI's innovations are expected to significantly improve diagnostic processes and patient outcomes in the healthcare sector.
See More
SPECTRAL AI APPOINTS DAVID MCGUIRE, CPA, AS CFO
- New Appointment: Spectral AI has named David McGuire as its Chief Financial Officer (CFO).
- Background: David McGuire is a Certified Public Accountant (CPA) with extensive experience in financial management.
See More
Spectral AI (MDAI) Q4 2025 Earnings Transcript
See More
